Uncategorized

IPO Weekly Recap: Redfin, Sienna shine in debuts

It was an extremely strong week for IPOs as two of the three deals opened higher than 25% above their respective offering prices. Redfin Corporation (Nasdaq: RDFN) was considered many-multiple times oversubscribed by IPO Boutique’s sources and priced its offering $1.00 above the $12-$14 range. ‘RDFN’ opened with a first trade of $19.56 or 30.4% higher.[…]

Weekly Secondary Performance Report (6.30.17)

You can Subscribe to IPO Boutique’s Secondary Only Service by clicking here:   This past week 15 secondary offerings came to market and IPO Boutique placed BUY ratings on 6 of them. This week, $2.25bn was raised by companies in the secondary market. The average gain of BUY rated offerings this week at first trade[…]

IPO Boutique Brief (6.1.17) — Calm before the storm, part 2?

SIGN UP FOR IPO BOUTIQUE’S FREE NEWSLETTER After a well-documented slow 2016…forecasters had predicted an active syndicate calendar in 2017. One analyst said 275 deals this year was possible…others were saying the pipeline was considerably backed up. The availability of private funding and lack of urgency to go public continue to be logical reasoning behind[…]

Secondaries Announced 5.16.2017

IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]

Secondaries Announced 5.15.2017

IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]

New Filings & Updated Terms (5.5.17)

NEW FILINGS Company: GPM Petroleum LP Symbol: GPMP Price: TBD Description: They are a growth-oriented Delaware limited partnership formed by GPM to engage in the wholesale distribution of motor fuels on a fixed fee per gallon basis to GPM-controlled convenience stores and third parties. Trade Date: TBD Shares: TBD Underwriter(s): Raymond James, Wells Fargo Securities,[…]

Presidio prices IPO at low-end of the range, to debut Friday

Presidio Inc. (Nasdaq: PSDO) — According to the underwriter, Presidio Inc priced its IPO at the low-end of the range. ‘PSDO’ priced 16.7mm shares at $14.00 and will debut on Friday (3/10).   Want to stay up to speed on IPO News & IPO Boutique? Subscribe to our FREE IPO NEWSLETTER If having real-time alerts for secondary offerings would be[…]

02.21.2017 Secondary Announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Tesoro Logistics LP Symbol: TLLP Price: Last trade $59.29 Description: Re-offer range $56.80-$58.70 Trade Date: 2/22 Shares: 5 million Underwriter(s)Citigroup, Deutsche[…]

Secondaries announced 01.25.2017

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Entellus Medical, Inc. Symbol: ENTL Price: Last trade $19.39 Description: Re-offer range $17.00-$18.00 Trade Date: 1/26 Shares: 3.1 million Underwriter(s)BofA Merrill[…]

Secondaries announced 12.08.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Recro Pharma, Inc. Symbol: REPH Price: Last trade $6.99 Trade Date: 12/13 Shares: 5.7 million Underwriter(s)Piper Jaffray Rating=Subscription Needed Company: Valley[…]

Secondaries announced 12.01.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: SM Energy Symbol: SM Price: Last trade $40.17 Description: Re-offer range $37.50-$39.50 Trade Date: 12/2 Shares: 8 million Underwriter(s)J.P. Morgan, BofA[…]

Secondaries announced 10.12.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: MercadoLibre, Inc. Symbol: MELI Price: Last trade $183.21 Trade Date: 10/14 Shares: 5.5 million Underwriter(s)Morgan Stanley, J.P. Morgan Rating=Subscription Needed

Secondaries announced 9/26/2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Nordic American Tankers Limited Symbol: NAT Price: Last trade $10.68 Description: Re-offer $10.00 Trade Date: 9/27 Shares: 11 million Underwriter(s)Morgan Stanley,[…]

Secondaries announced 9.22.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Home BancShares, Inc. Symbol: HOMB Price: Last trade $22.67 Description: No re-offer available Trade Date: 9/23 Shares: 2.65 million Underwriter(s) Stephens[…]

Moderna Therapeutics Making Waves at JPM HealthCare Conference

Prior to last year’s J.P. Morgan Healthcare Conference, Moderna Therapeutics made waves with the largest biotech private funding round ever–a $446m round in December 2014. And now, the news is spreading to the masses. Moderna Therapeutics, a company that focuses on using messenger RNA, or mRNA, to spur the production of human proteins within patient[…]

Scroll to top
error: Content is protected !!